Protara Therapeutics, Inc. Business Acquisition, Pro Forma Net Income (Loss)
Protara Therapeutics, Inc. (TARA) reported Business Acquisition, Pro Forma Net Income (Loss) of -$33.75 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2022-03-09
- Protara Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2020-12-31 was -$8.81M.
- Protara Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2019-12-31 was -$4.13M.
- Protara Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2019-09-30 was -$3.89M.
- Protara Therapeutics, Inc. business acquisition, pro forma net income (loss) for fiscal 2021 was -$33.75M.
- Protara Therapeutics, Inc. business acquisition, pro forma net income (loss) for fiscal 2020 was -$33.75M.
- Protara Therapeutics, Inc. business acquisition, pro forma net income (loss) for fiscal 2019 was -$22.82M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$33.75M 10-K · filed 2022-03-09 | |||
| 2020-12-31 | -$8.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$33.75M 10-K · filed 2021-03-11 | ||
| 2020-09-30 | -$24.95M 10-Q · filed 2020-11-12 | |||
| 2019-12-31 | -$4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$8.02M derived: sum of 2 quarters · filed 2021-03-11 | -$22.82M 10-K · filed 2021-03-11 | |
| 2019-09-30 | -$3.89M 10-Q · filed 2020-11-12 | -$18.69M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |